| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.070 | PosttranslationalModification | phenotype | BEFREE | Interestingly, aberrant methylation of multiple cancer-related genes was significantly associated with EGFR wildtype tumors. | 30089603 | 2018 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | Activation of the EGF receptors EGFR (ErbB1) and HER2 (ErbB2) drives the progression of multiple cancer types through complex mechanisms that are still not fully understood. | 27793843 | 2017 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | Due to the lack of candidate biomarkers that consistently predict response to EGFR-inhibitor therapy across treatment setting and class of agent in SqCC of the lung and SCCHN, we explore the biology, genomics and patterns of response to EGFR-inhibitors to inform identification of potential biomarkers, highlighting several key molecules that have shown promise in preclinical studies and clinical trials across multiple cancer sites. | 28192747 | 2017 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | Herein, we assessed in ER-negative IBC cells a subset of chemicals from the EPA ToxCast set for their effect on EGFR activation and in multiple cancer phenotypic assays. | 28426875 | 2017 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | A global landscape of gene-pathway pairs showed that EGFR linked with multiple cancer-related biological pathways confers the highest risk of GBM. | 24911613 | 2014 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | Here we show that autophagy is induced in a dose-dependent manner by in vitro treatment of multiple cancer cell lines with EGFR-TKI. | 22954701 | 2012 | ||||
|
0.070 | Biomarker | phenotype | BEFREE | In summary, we have managed to overcome issues of stability and productivity of bispecific antibodies, discovered important antibody fusion protein design related differences on ADCC activity and receptor downmodulation and show that IGF-1R-EGFR antibodies represent an attractive therapeutic strategy to simultaneously target two key components de-regulated in multiple cancer types, with the ultimate goal to avoid the formation of resistance to therapy. | 22464987 | 2012 |